Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 3:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: dose level 3 Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Experimental Human Infection With Neisseria Gonorrhoeae

NCT03840811
View directory record Official record
Conditions
Gonococcal Infection
Interventions
Cefixime, Ceftriaxone, Ciprofloxacin, Neisseria gonorrhoeae strain FA1090 A26, Neisseria gonorrhoeae strain FA7537
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 36 Years · Male only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 22, 2021 · Synced Sep 23, 2026, 3:58 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of TAK-781 in Healthy Volunteers and in Participants With Non-Cirrhotic Primary Sclerosing Cholangitis (PSC)

NCT07229911
View directory record Official record
Conditions
Healthy Volunteers, Primary Sclerosing Cholangitis
Interventions
TAK-781, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 68 Years
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Sep 23, 2026, 3:58 PM EDT
Completed Phase 1 Interventional

Study to Evaluate DNL201 in Subjects With Parkinson's Disease

NCT03710707
View directory record Official record
Conditions
Parkinson Disease
Interventions
DNL201, Placebo
Drug
Lead sponsor
Denali Therapeutics Inc.
Industry
Eligibility
30 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
7
States / cities
Long Beach, California • Aurora, Colorado • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2020 · Synced Sep 23, 2026, 3:58 PM EDT
Withdrawn Phase 1Phase 2 Interventional

OSI-906 With Gemcitabine and Erlotinib for Metastatic Ductal Adenocarcinoma of the Pancreas

NCT01600807
View directory record Official record
Conditions
Pancreatic Cancer, Metastatic
Interventions
Gemcitabine, Erlotinib, OSI-906, Gemcitabine, Erlotinib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 25, 2013 · Synced Sep 23, 2026, 3:58 PM EDT
Active, not recruiting Phase 1 Interventional

Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL

NCT03240211
View directory record Official record
Conditions
PTCL, CTCL
Interventions
Pembrolizumab, Pralatrexate, Decitabine
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 90 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 23, 2026, 3:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Breast Milk Pharmacokinetics of Olanzapine and Samidorphan

NCT05547100
View directory record Official record
Conditions
Focus of Study is on Healthy Lactating Women
Interventions
LYBALVI
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Sep 23, 2026, 3:58 PM EDT
Completed Phase 1 Interventional

Study of VX-985 in Subjects With Chronic Hepatitis C

NCT01144936
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
VX-985 or matching placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 64 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
3
States / cities
Overland Park, Kansas • Baltimore, Maryland • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Mar 8, 2011 · Synced Sep 23, 2026, 3:58 PM EDT
Completed Phase 3 Interventional Results available

Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma

NCT00689936
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Lenalidomide and low-dose dexamethasone, Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles, Melphalan, Prednisone and Thalidomide
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
1,623 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
32
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Sep 23, 2026, 3:58 PM EDT
Completed Phase 2 Interventional

DUR-928 in Patients With Alcoholic Hepatitis

NCT03917407
View directory record Official record
Conditions
Alcoholic Hepatitis
Interventions
DUR-928 (Moderate AH), DUR-928 (Severe AH)
Drug
Lead sponsor
Craig James McClain
Other
Eligibility
21 Years to 67 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Sep 23, 2026, 3:58 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis

NCT05050136
View directory record Official record
Conditions
Primary Biliary Cholangitis, PBC
Interventions
Volixibat, Placebo
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
44
States / cities
Coronado, California • Los Angeles, California • Sacramento, California + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 23, 2026, 3:58 PM EDT
Active, not recruiting Phase 2 Interventional

The Prevention of Progression to Pancreatic Cancer Trial (The 3P-C Trial)

NCT04207944
View directory record Official record
Conditions
IPMN, IPMN, Pancreatic
Interventions
Sulindac 400 MG, Placebo
Drug · Other
Lead sponsor
Duke University
Other
Eligibility
21 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
4
States / cities
Baltimore, Maryland • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 23, 2026, 3:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study of a Tablet Form of ABBV-722 Taken With and Without Food in Healthy Adult Participants

NCT07361367
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ABBV-722
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Sep 23, 2026, 3:58 PM EDT
Completed Phase 2 Interventional Results available

A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight

NCT06124807
View directory record Official record
Conditions
Obesity, Overweight and Obesity
Interventions
Mazdutide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
29
States / cities
Chandler, Arizona • Scottsdale, Arizona • Tucson, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 23, 2026, 3:58 PM EDT
Terminated Phase 3 Interventional Results available

221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease

NCT02477800
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Aducanumab (BIIB037), Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
50 Years to 85 Years
Enrollment
1,653 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
59
States / cities
Phoenix, Arizona • Tucson, Arizona • Fullerton, California + 52 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2021 · Synced Sep 23, 2026, 3:58 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Remifentanil in Adults With OSA

NCT02898792
View directory record Official record
Conditions
Apnea, Sleep
Interventions
Targeted infusion of remifentanil
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 3, 2018 · Synced Sep 23, 2026, 3:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study of PF-06651600 Capsules Relative to Tablets and Estimation of Food Effect on Capsules.

NCT04390776
View directory record Official record
Conditions
Healthy Participants
Interventions
PF-06651600
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
164 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Hollywood, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Sep 23, 2026, 3:58 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Caffeine on Heart Function

NCT02401776
View directory record Official record
Conditions
Fatigue, Tachycardia
Interventions
Monster Energy Drink, Coffee
Dietary Supplement
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 35 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Sep 23, 2026, 3:58 PM EDT
Active, not recruiting Phase 1 Interventional

Study Evaluating a Stereotactic Boost/Treatment for Recurrent or Metastatic Cancer of the Head and Neck

NCT02474368
View directory record Official record
Conditions
Recurrent Head and Neck Carcinoma, Head and Neck Cancer Metastatic, Head or Neck Cancer
Interventions
Intensity Modulated Radiation Therapy (IMRT), Cisplatin, Stereotactic Body Radiotherapy (SBRT)
Radiation · Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 23, 2026, 3:58 PM EDT
Completed Phase 3 Interventional Results available

Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.

NCT00611026
View directory record Official record
Conditions
Overactive Bladder
Interventions
Tolterodine ER, Placebo, Fesoterodine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
2,417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
102
States / cities
Enterprise, Alabama • Mobile, Alabama • Montgomery, Alabama + 85 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2011 · Synced Sep 23, 2026, 3:58 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

MEK162 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic Function

NCT02050815
View directory record Official record
Conditions
Hepatic Impairment
Interventions
MEK162
Drug
Lead sponsor
Array Biopharma, now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
5
States / cities
Lakewood, Colorado • Miami, Florida • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Sep 23, 2026, 3:58 PM EDT
Completed Phase 2 Interventional Results available

Selinexor Treatment of Refractory Myeloma

NCT02336815
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Selinexor, Dexamethasone
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
36
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Duarte, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Sep 23, 2026, 3:58 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Apremilast for Alcohol Use Disorder Treatment in Women and Men

NCT06324435
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Apremilast
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Sep 23, 2026, 3:58 PM EDT
Active, not recruiting Early Phase 1 Interventional

Study of the Effects of Pre-surgical Aerobic Exercise on Patients With Solid Tumors

NCT03813615
View directory record Official record
Conditions
Preoperative Aerobic Training, Solid Tumors
Interventions
treadmill walking (Proof-of-Concept), treadmill walking Dose-Finding / Escalation
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
19 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
8
States / cities
Los Angeles, California • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 23, 2026, 3:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Clinical Trial of PGDM1400 and PGT121 and VRC07-523LS Monoclonal Antibodies in HIV-infected and HIV-uninfected Adults

NCT03205917
View directory record Official record
Conditions
HIV Infections
Interventions
PGDM1400/Placebo (3mg/kg IV), PGDM1400/Placebo (10mg/kg IV), PGDM1400/Placebo (30mg/kg IV), PGDM1400 + PGT121/Placebo (3mg/kg + 3mg/kg IV), PGDM1400 + PGT121/Placebo (10mg/kg + 10mg/kg IV), PGDM1400 + PGT121/Placebo (30mg/kg + 30mg/kg IV), PGDM1400 + PGT121 + VRC07-523LS (20mg/kg + 20mg/kg + 20 mg/kg IV), PGDM1400 + PGT121 (MTD IV)
Biological
Lead sponsor
International AIDS Vaccine Initiative
Network
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 13, 2020 · Synced Sep 23, 2026, 3:58 PM EDT